Adicet bio reports inducement grants under nasdaq listing rule 5635(c)(4)

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on september 30, 2024. four individuals were hired by adicet in september 2024. in the aggregate, adicet granted new hires non-qualified stock options to purchase 33,600 shares of adicet's common stock with an exercise price of $1.
ACET Ratings Summary
ACET Quant Ranking